Nahel Elias1, A Benedict Cosimi, Tatsuo Kawai. 1. Transplant Center and Division of Transplant Surgery, Department of Surgery, Massachusetts General Hospital, Harvard Medical School.
Abstract
PURPOSE OF REVIEW: This review summarizes the current state of clinical trials for tolerance induction of human leukocyte antigen-matched or mismatched renal allografts via peritransplant infusion of donor bone marrow-derived products. Recent efforts to apply infusion of expanded regulatory T-cell preparations to minimize immunosuppressive dosages are also reviewed. RECENT FINDINGS: Three centers in the United States have reported clinical trials for tolerance induction in recipients of living donor kidney transplants via donor hematopoietic stem cell transplantation. They have observed varying degrees of successful renal allograft tolerance induction following the establishment of either transient or persistent donor chimerism.A more recent clinical trial planned to evaluate administration of regulatory T cells to harness the immune response has recently been initiated in eight centers in Europe and the United States. SUMMARY: Tolerance induction in clinical kidney transplantation from live donors has been achieved by donor hematopoietic stem cell transplantation. Improving the consistency and safety of tolerance induction and extending successful protocols to other organs, as well as to organs from deceased donors, are critical next steps to bringing tolerance to a wider range of clinical applications.
PURPOSE OF REVIEW: This review summarizes the current state of clinical trials for tolerance induction of human leukocyte antigen-matched or mismatched renal allografts via peritransplant infusion of donor bone marrow-derived products. Recent efforts to apply infusion of expanded regulatory T-cell preparations to minimize immunosuppressive dosages are also reviewed. RECENT FINDINGS: Three centers in the United States have reported clinical trials for tolerance induction in recipients of living donor kidney transplants via donor hematopoietic stem cell transplantation. They have observed varying degrees of successful renal allograft tolerance induction following the establishment of either transient or persistent donor chimerism.A more recent clinical trial planned to evaluate administration of regulatory T cells to harness the immune response has recently been initiated in eight centers in Europe and the United States. SUMMARY: Tolerance induction in clinical kidney transplantation from live donors has been achieved by donor hematopoietic stem cell transplantation. Improving the consistency and safety of tolerance induction and extending successful protocols to other organs, as well as to organs from deceased donors, are critical next steps to bringing tolerance to a wider range of clinical applications.
Authors: R N Smith; M Matsunami; B A Adam; I A Rosales; T Oura; A B Cosimi; T Kawai; M Mengel; R B Colvin Journal: Am J Transplant Date: 2018-02-17 Impact factor: 8.086
Authors: Carolina Purroy; Robert L Fairchild; Toshiaki Tanaka; William M Baldwin; Joaquin Manrique; Joren C Madsen; Robert B Colvin; Alessandro Alessandrini; Bruce R Blazar; Miguel Fribourg; Chiara Donadei; Umberto Maggiore; Peter S Heeger; Paolo Cravedi Journal: J Am Soc Nephrol Date: 2017-03-16 Impact factor: 10.121
Authors: Alexandre G Lellouch; Alec R Andrews; Gaelle Saviane; Zhi Yang Ng; Ilse M Schol; Marion Goutard; Amon-Ra Gama; Ivy A Rosales; Robert B Colvin; Laurent A Lantieri; Mark A Randolph; Gilles Benichou; Curtis L Cetrulo Journal: Front Immunol Date: 2022-05-10 Impact factor: 8.786
Authors: Nina Pilat; Benedikt Mahr; Lukas Unger; Karin Hock; Christoph Schwarz; Andreas M Farkas; Ulrike Baranyi; Fritz Wrba; Thomas Wekerle Journal: JCI Insight Date: 2016-05-19